How to Preserve Muscle on GLP-1 Medications: Evidence-Based Strategies

GLP-1 medications like semaglutide and tirzepatide produce significant weight loss, but 25-40% of that loss can come from lean muscle mass rather than fat. This matters because muscle drives metabolism, prevents falls, and supports long-term health. The good news: research shows you can minimize or even eliminate muscle loss with the right combination of resistance training, adequate protein intake, and targeted supplementation.

This guide breaks down the clinical evidence and gives you a practical action plan.

Why Muscle Loss on GLP-1s Happens

GLP-1 receptor agonists don't directly attack muscle tissue. The muscle loss occurs because these medications suppress appetite so effectively that many patients enter a severe calorie and protein deficit without realizing it.

When you consume fewer calories and less protein, your body breaks down muscle tissue for energy and amino acids. The faster you lose weight, the more muscle you tend to lose.

What the Clinical Trials Show

The numbers vary depending on the study and medication:

According to a 2024 review in Diabetes, Obesity & Metabolism, lean mass loss ranges from 15% to 60% of total weight lost depending on the patient, dose, and whether any protective measures are taken.

Tirzepatide shows a somewhat better lean mass preservation profile (26-38% of weight from lean mass) compared to semaglutide (39-45%), possibly due to GIP receptor activation providing some anabolic signaling.

Does Lean Mass Loss Equal Muscle Loss?

An important clarification: "lean mass" on a body composition scan doesn't mean pure muscle.

Fat tissue itself contains water and connective tissue that register as lean mass. When you lose fat, some measured lean mass disappears too. Liver and organ mass also decreases with weight loss.

A 2026 study in Cell Reports Medicine examined this directly in mice and found that GLP-1 medications reduced body fat alongside a small decrease in lean body mass, but among lean tissues, loss of liver mass exceeded changes in muscle mass.

This doesn't mean muscle loss isn't real. It is. But the headline numbers often overstate the direct impact on skeletal muscle.

The Sarcopenia Concern for Older Adults

For adults over 65, the stakes are higher. Natural aging already reduces skeletal muscle mass by 12-16%, and sarcopenia (clinically significant muscle loss) affects up to half of adults over 80.

A retrospective cohort study found that elderly patients on semaglutide showed accelerated declines in handgrip strength compared to those on sitagliptin, particularly at higher doses and in those with pre-existing low muscle mass.

The editorial board at Annals of Internal Medicine warned that GLP-1 medications may exacerbate sarcopenia in seniors, increasing risk of falls, fractures, and disability.

This doesn't mean older adults shouldn't use GLP-1s. It means they need to be more aggressive about muscle preservation strategies.

The Four Pillars of Muscle Preservation

Research consistently points to four interventions that protect lean mass during GLP-1 therapy.

1. Resistance Training: Non-Negotiable

This is the single most important intervention. Without resistance training, you will lose muscle. With it, you can preserve most or all of your lean mass.

What the research shows:

• People who do resistance training while taking GLP-1 medications reduce muscle loss by up to 30%
• A 2025 case series of patients on semaglutide and tirzepatide who trained 3-5 days per week showed lean mass changes of only -6.9% to +5.8%, compared to the typical 25-40% loss ratio
• Two out of three patients in that case series actually gained lean mass while losing significant body fat

Minimum effective protocol:

• 2-3 resistance training sessions per week
• Hit all major muscle groups: legs, back, chest, shoulders, arms, core
• Focus on compound movements: squats, deadlifts, rows, presses, pull-ups
• Progressive overload: gradually increase weight, reps, or sets over time
• Allow 48 hours between training the same muscle group

If you're new to strength training, start with bodyweight exercises or machines. The stimulus matters more than the specific method. Push-ups, squats, lunges, and planks done consistently will preserve more muscle than an elaborate program you don't follow.

2. Protein Intake: 1.2-1.6 g/kg Daily

When you're losing weight on a GLP-1 medication, protein becomes even more important. Your body needs amino acids to maintain and repair muscle tissue, and those amino acids must come from food since you're not storing them.

Clinical recommendations:

The optimal target is 1.2-1.6 grams of protein per kilogram of body weight per day. Some researchers recommend up to 2.0 g/kg for those doing resistance training or experiencing rapid weight loss.

Practical examples:

Distribution matters:

Your body can only synthesize a limited amount of protein at once. Spreading intake across 3-4 meals (25-30g per meal) is more effective than loading it into one meal.

Practical tips given reduced appetite:

• Prioritize protein at the start of meals before satiety kicks in
• Choose protein-dense foods: Greek yogurt, eggs, chicken, fish, lean beef
• Consider protein shakes if solid food is difficult
• Track intake for the first few weeks until you build habits

3. Gradual Weight Loss: Slower Is Better

Rapid weight loss (more than 1% of body weight per week) significantly increases the proportion lost from lean mass.

GLP-1 medications can drive very fast initial weight loss, especially in the first few months. While you can't fully control this, you can:

• Start at lower doses and titrate slowly as tolerated
• Ensure you're eating enough total calories (not just protein)
• Avoid stacking additional calorie-restriction strategies on top of the medication

The goal isn't to slow weight loss artificially, but to ensure the weight you're losing is primarily fat.

4. Supplementation: Creatine and Beyond

Creatine monohydrate has the strongest evidence base for muscle preservation during weight loss.

While no trials have directly studied creatine in GLP-1 users specifically, the existing research is compelling:

• Meta-analyses show creatine plus resistance training increases lean body mass by an average of 1.32 kg compared to training alone
• A 2025 study found creatine paired with resistance training increased fat-free mass by 1.39 kg on average
• During calorie restriction, creatine supplementation helps preserve up to 60% more lean mass compared to non-supplemented controls

Protocol: 3-5 grams of creatine monohydrate daily. No loading phase needed. Take it consistently at any time of day.

Safety: A 2020 systematic review confirmed that daily creatine intake of 3-5g poses no risk to kidney health in healthy adults.

Other supplements with supporting evidence:

• HMB (β-Hydroxy β-Methylbutyrate): May reduce muscle protein breakdown during calorie restriction
• Vitamin D: Deficiency is linked to muscle weakness; supplement if levels are low
• Omega-3 fatty acids: Some evidence for supporting muscle protein synthesis in older adults

Emerging Pharmacological Solutions

Researchers are actively developing medications that address muscle loss directly. The most promising:

Bimagrumab + Semaglutide

Bimagrumab is a monoclonal antibody that blocks activin type II receptors, promoting muscle growth. The BELIEVE Phase 2b trial tested it in combination with semaglutide in 507 participants.

Results at 72 weeks:

The combination achieved 92.8% of weight loss from fat mass, compared to 71.8% for semaglutide alone. Bimagrumab alone actually increased lean mass.

Eli Lilly acquired Versanis Bio and is advancing bimagrumab into Phase 3 trials. If approved, it could fundamentally change how we approach weight loss medications.

Trevogrumab + Semaglutide (COURAGE Trial)

Regeneron's COURAGE trial is testing trevogrumab, another anti-myostatin antibody, combined with semaglutide. Interim results show patients preserved more lean mass with greater fat loss compared to semaglutide alone.

Pemvidutide

This GLP-1/glucagon dual agonist showed better muscle preservation in Phase 2 trials. In the MOMENTUM trial, only 21.9% of weight lost was lean mass, roughly half the ratio seen with semaglutide.

A Practical Action Plan

Here's what to do if you're starting or currently taking a GLP-1 medication:

Week 1: Establish baselines

• Get a body composition measurement (DEXA scan is gold standard)
• Calculate your protein target (weight in kg × 1.4)
• Schedule 2-3 resistance training sessions per week

Ongoing: Daily habits

• Track protein intake until it becomes automatic
• Take 3-5g creatine daily
• Eat protein first at each meal
• Complete all scheduled training sessions

Monthly: Monitor progress

• Track strength gains (are your weights going up?)
• Note any functional changes (stairs easier? carrying groceries?)
• Consider repeat body composition scans every 3-6 months

Red flags to discuss with your provider:

• Significant weakness or difficulty with daily activities
• Unexplained fatigue beyond typical GLP-1 adjustment
• Rapid weight loss exceeding 1% of body weight weekly for extended periods

Key Takeaways

• GLP-1 medications cause muscle loss indirectly through reduced food intake, not direct muscle breakdown
• The 25-40% lean mass loss figure from trials likely overstates actual skeletal muscle loss
• Resistance training is the most important protective intervention, reducing muscle loss by up to 30%
• Protein intake of 1.2-1.6 g/kg daily, spread across meals, supports muscle preservation
• Creatine supplementation (3-5g daily) has strong evidence for preserving lean mass during weight loss
• Combination therapies like bimagrumab + semaglutide show promise for near-complete muscle preservation
• Start muscle preservation strategies on day one, not after you've already lost lean mass

Frequently Asked Questions

How much muscle will I lose on Ozempic or Wegovy?

Without protective measures, clinical trials show 25-45% of weight lost may come from lean mass. However, with consistent resistance training and adequate protein intake, you can reduce this significantly or even maintain your lean mass while losing primarily fat.

Can I build muscle while taking a GLP-1 medication?

Yes. Case studies show patients who prioritize resistance training and protein actually gained lean mass while losing fat on semaglutide and tirzepatide. The medication doesn't prevent muscle growth.

Should older adults avoid GLP-1 medications due to sarcopenia risk?

Not necessarily, but they should be more cautious. Older adults benefit most from aggressive muscle preservation strategies: higher protein targets, consistent strength training, and potentially more frequent monitoring of muscle function.

Is tirzepatide better than semaglutide for preserving muscle?

Tirzepatide shows a slightly better lean mass preservation profile (26-38% of weight from lean mass vs. 39-45% for semaglutide), possibly due to GIP receptor activation. However, the difference isn't dramatic, and individual factors like diet and exercise matter more.

When will muscle-preserving GLP-1 combinations be available?

Bimagrumab is in Phase 3 trials and could reach market within 2-3 years if successful. Several other anti-myostatin antibodies are also in development. Until then, lifestyle interventions remain the primary strategy.

---

This content is for informational purposes only and does not constitute medical advice. Consult a healthcare provider before starting any peptide therapy, exercise program, or supplementation regimen.

Sources

• Preservation of lean soft tissue during weight loss with GLP-1 RAs (PMC)
• New GLP-1 Therapies and Muscle Preservation (American Diabetes Association)
• Muscle Mass and GLP-1 Receptor Agonists (Circulation)
• Changes in lean body mass with GLP-1 therapies (Diabetes, Obesity and Metabolism)
• GLP-1 medicines and muscle function (Cell Reports Medicine)
• GLP-1 Muscle Loss Prevention (U.S. News Health)
• Ozempic and Muscle Loss (Cleveland Clinic)
• Sarcopenia in the era of GLP-1 RAs (American Journal of Medicine)
• BELIEVE Trial Results (Nature Medicine)
• Dietary supplement considerations during GLP-1 RA treatment (ScienceDirect)